Alexandra M Nicholson1, NiCole A Finch1, Colleen S Thomas1, Aleksandra Wojtas1, Nicola J Rutherford1, Michelle M Mielke1, Rosebud O Roberts1, Bradley F Boeve1, David S Knopman1, Ronald C Petersen1, Rosa Rademakers2. 1. From the Department of Neuroscience (A.M.N., N.A.F., A.W., N.J.R., R.R.) and Division of Biomedical Statistics and Informatics (C.S.T.), Mayo Clinic, Jacksonville, FL; and Division of Epidemiology, Department of Health Sciences Research (M.M.M., R.O.R.) and Department of Neurology (R.O.R., B.F.B., D.S.K., R.C.P.), Mayo Clinic, Rochester, MN. 2. From the Department of Neuroscience (A.M.N., N.A.F., A.W., N.J.R., R.R.) and Division of Biomedical Statistics and Informatics (C.S.T.), Mayo Clinic, Jacksonville, FL; and Division of Epidemiology, Department of Health Sciences Research (M.M.M., R.O.R.) and Department of Neurology (R.O.R., B.F.B., D.S.K., R.C.P.), Mayo Clinic, Rochester, MN. rademakers.rosa@mayo.edu.
Abstract
OBJECTIVE: We aimed to investigate the relationship between plasma and CSF progranulin (PGRN) levels. METHODS: Plasma and CSF PGRN were measured in a cohort of 345 subjects from the Mayo Clinic Study of Aging by ELISA. Single nucleotide polymorphism genotyping was performed using TaqMan assays. Associations between PGRN and sex, age at sample collection, diagnosis, single nucleotide polymorphism genotypes (GRN, SORT1, and APOE), and Pittsburgh compound B score were explored separately in CSF and plasma using single variable linear regression models. Pearson partial correlation coefficient was used to estimate the correlation of PGRN in CSF and plasma. RESULTS: Plasma (p = 0.0031) and CSF (p = 0.0044) PGRN significantly increased with age, whereas plasma PGRN levels were 7% lower (p = 0.0025) and CSF PGRN levels 5% higher (p = 0.0024) in male compared with female participants. Correcting for age and sex, higher plasma PGRN was associated with higher CSF PGRN (partial r = 0.17, p = 0.004). In plasma, both rs5848 (GRN; p = 0.002) and rs646776 (SORT1; p = 3.56E-7) were associated with PGRN, while only rs5848 showed highly significant association in CSF (p = 5.59E-14). Age, sex, rs5848 genotype, and plasma PGRN together accounted for only 18% of the variability observed in CSF PGRN. CONCLUSIONS: While some correlation exists between plasma and CSF PGRN, age, sex, and genetic factors differently affect PGRN levels. Therefore, caution should be taken when using plasma PGRN to predict PGRN changes in the brain. These findings further highlight that plasma PGRN levels may not accurately predict clinical features or response to future frontotemporal lobar degeneration therapies.
OBJECTIVE: We aimed to investigate the relationship between plasma and CSFprogranulin (PGRN) levels. METHODS: Plasma and CSFPGRN were measured in a cohort of 345 subjects from the Mayo Clinic Study of Aging by ELISA. Single nucleotide polymorphism genotyping was performed using TaqMan assays. Associations between PGRN and sex, age at sample collection, diagnosis, single nucleotide polymorphism genotypes (GRN, SORT1, and APOE), and Pittsburgh compound B score were explored separately in CSF and plasma using single variable linear regression models. Pearson partial correlation coefficient was used to estimate the correlation of PGRN in CSF and plasma. RESULTS: Plasma (p = 0.0031) and CSF (p = 0.0044) PGRN significantly increased with age, whereas plasma PGRN levels were 7% lower (p = 0.0025) and CSFPGRN levels 5% higher (p = 0.0024) in male compared with female participants. Correcting for age and sex, higher plasma PGRN was associated with higher CSFPGRN (partial r = 0.17, p = 0.004). In plasma, both rs5848 (GRN; p = 0.002) and rs646776 (SORT1; p = 3.56E-7) were associated with PGRN, while only rs5848 showed highly significant association in CSF (p = 5.59E-14). Age, sex, rs5848 genotype, and plasma PGRN together accounted for only 18% of the variability observed in CSFPGRN. CONCLUSIONS: While some correlation exists between plasma and CSFPGRN, age, sex, and genetic factors differently affect PGRN levels. Therefore, caution should be taken when using plasma PGRN to predict PGRN changes in the brain. These findings further highlight that plasma PGRN levels may not accurately predict clinical features or response to future frontotemporal lobar degeneration therapies.
Authors: Y M Kuo; M R Emmerling; H C Lampert; S R Hempelman; T A Kokjohn; A S Woods; R J Cotter; A E Roher Journal: Biochem Biophys Res Commun Date: 1999-04-21 Impact factor: 3.575
Authors: E Matsubara; J Ghiso; B Frangione; M Amari; Y Tomidokoro; Y Ikeda; Y Harigaya; K Okamoto; M Shoji Journal: Ann Neurol Date: 1999-04 Impact factor: 10.422
Authors: R Motter; C Vigo-Pelfrey; D Kholodenko; R Barbour; K Johnson-Wood; D Galasko; L Chang; B Miller; C Clark; R Green Journal: Ann Neurol Date: 1995-10 Impact factor: 10.422
Authors: N Ida; T Hartmann; J Pantel; J Schröder; R Zerfass; H Förstl; R Sandbrink; C L Masters; K Beyreuther Journal: J Biol Chem Date: 1996-09-13 Impact factor: 5.157
Authors: M Kanai; E Matsubara; K Isoe; K Urakami; K Nakashima; H Arai; H Sasaki; K Abe; T Iwatsubo; T Kosaka; M Watanabe; Y Tomidokoro; M Shizuka; K Mizushima; T Nakamura; Y Igeta; Y Ikeda; M Amari; T Kawarabayashi; K Ishiguro; Y Harigaya; K Wakabayashi; K Okamoto; S Hirai; M Shoji Journal: Ann Neurol Date: 1998-07 Impact factor: 10.422
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca Journal: Neuroepidemiology Date: 2008-02-07 Impact factor: 3.282
Authors: Hideyuki Takahashi; Zoe A Klein; Sarah M Bhagat; Adam C Kaufman; Mikhail A Kostylev; Tsuneya Ikezu; Stephen M Strittmatter Journal: Acta Neuropathol Date: 2017-01-09 Impact factor: 17.088
Authors: Leonel T Takada; Valeria S Bahia; Henrique C Guimarães; Thais V M M Costa; Thiago C Vale; Roberta D Rodriguez; Fabio H G Porto; João C B Machado; Rogério G Beato; Karolina G Cesar; Jerusa Smid; Camila F Nascimento; Lea T Grinberg; Sonia M D Brucki; Jessica R Maximino; Sarah T Camargos; Gerson Chadi; Paulo Caramelli; Ricardo Nitrini Journal: Alzheimer Dis Assoc Disord Date: 2016 Oct-Dec Impact factor: 2.703
Authors: Emily Feneberg; Petra Steinacker; Alexander Erich Volk; Jochen Hans Weishaupt; Marc Axel Wollmer; Adam Boxer; Hayrettin Tumani; Albert Christian Ludolph; Markus Otto Journal: J Neural Transm (Vienna) Date: 2015-12-11 Impact factor: 3.575